To test the impact of IDH1-R132H and ATRX on routine diagnostic neuropathology and their evaluation for progression of gliomas, we analyzed a series of 211 serial sampling of glioma tissues, including 103 astrocytomas (A, AA), 25 oligodendrogliomas (O, AO), 123 oligoastrocytomas (OA, AOA) and 181 glioblastomas (pGBM, sGBM, rGBM) by immunohistochemistry for IDH1-R132H and ATRX evaluation. This evidence concerns the gene ATRX and central nervous system cancer.